A Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Comparison Study in Patients with Non-Small Cell Lung Cancer-Cachexia
Latest Information Update: 18 May 2022
Price :
$35 *
At a glance
- Drugs Anamorelin (Primary)
- Indications Cachexia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 22 Jan 2021 According to an ONO Pharmaceutical media release, based on the results of ONO-7643-04 and ONO-7643-05 studies, the company has received the manufacturing and marketing approval of Adlumiz (anamorelin hydrochloride) Tablet 50mg (Adlumiz), for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer in Japan.
- 27 Nov 2018 According to an ONO Pharmaceuticals media release, base don the results of ONO-7643-04 and ONO-7643-05 study, company has submitted application for manufacturing and marketing approval of anamorelin hydrochloride (ONO-7643) for improvement of body weight loss and anorexia in patients with cancer cachexia in Japan.
- 04 Dec 2017 Results published in the Cancer